Syndecan-1 (CD138) Immunoreactivity in Bone Marrow Biopsies of Multiple Myeloma: Shed Syndecan-1 Accumulates in Fibrotic Regions, Modern Pathology, vol.14, issue.10, pp.1052-1060, 2001. ,
DOI : 10.1038/modpathol.3880435
Heparan sulfate proteoglycan as a plasma membrane carrier, Trends in Biochemical Sciences, vol.28, issue.3, pp.145-51, 2003. ,
DOI : 10.1016/S0968-0004(03)00031-8
Functions of Cell Surface Heparan Sulfate Proteoglycans, Annual Review of Biochemistry, vol.68, issue.1, pp.729-77, 1999. ,
DOI : 10.1146/annurev.biochem.68.1.729
Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases, Nature, vol.387, issue.6632, pp.512-518, 1997. ,
DOI : 10.1038/387512a0
The deaf and the dumb: the biology of ErbB-2 and ErbB-3, Experimental Cell Research, vol.284, issue.1, pp.54-65, 2003. ,
DOI : 10.1016/S0014-4827(02)00101-5
The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens, Human Pathology, vol.30, issue.12, pp.1405-1416, 1999. ,
DOI : 10.1016/S0046-8177(99)90160-0
Syndecans: proteoglycan regulators of cell-surface microdomains?, Nature Reviews Molecular Cell Biology, vol.4, issue.12, pp.926-963, 2003. ,
DOI : 10.1038/nrm1257
Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays, Blood, vol.98, issue.3, pp.771-780, 2001. ,
DOI : 10.1182/blood.V98.3.771
Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma, Blood, vol.99, issue.4, pp.1405-1415, 2002. ,
DOI : 10.1182/blood.V99.4.1405
Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma, British Journal of Haematology, vol.99, issue.2, pp.368-71, 1997. ,
DOI : 10.1046/j.1365-2141.1997.3893203.x
EGF receptor ligands, Experimental Cell Research, vol.284, issue.1, pp.2-13, 2003. ,
DOI : 10.1016/S0014-4827(02)00105-2
Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation, Cell Death and Differentiation, vol.26, issue.6, pp.637-685, 2005. ,
DOI : 10.1038/sj.cdd.4401647
Heparin-binding EGF-like growth factor stimulation of smooth muscle cell migration: dependence on interactions with cell surface heparan sulfate, The Journal of Cell Biology, vol.122, issue.4, pp.933-973, 1993. ,
DOI : 10.1083/jcb.122.4.933
The ErbB receptors and their role in cancer progression, Experimental Cell Research, vol.284, issue.1, pp.99-110, 2003. ,
DOI : 10.1016/S0014-4827(02)00099-X
ERBB receptors and cancer: the complexity of targeted inhibitors, Nature Reviews Cancer, vol.7, issue.5, pp.341-54, 2005. ,
DOI : 10.1021/jm00130a020
Identification of proteoglycans as the APRIL-specific binding partners, The Journal of Experimental Medicine, vol.103, issue.9, pp.1375-83, 2005. ,
DOI : 10.1002/eji.1830221136
The Effect of Low Molecular Weight Heparin on Survival in Patients With Advanced Malignancy, Journal of Clinical Oncology, vol.23, issue.10, pp.2130-2135, 2005. ,
DOI : 10.1200/JCO.2005.03.134
Management of multiple myeloma: a systematic review and critical appraisal of published studies, The Lancet Oncology, vol.4, issue.5, pp.293-304, 2003. ,
DOI : 10.1016/S1470-2045(03)01077-5
Analysis of high density expression microarrays with signed-rank call algorithms, Bioinformatics, vol.18, issue.12, pp.1593-1602, 2002. ,
DOI : 10.1093/bioinformatics/18.12.1593
ARIA can be released from extracellular matrix through cleavage of a heparin-binding domain, The Journal of Cell Biology, vol.130, issue.1, pp.127-162, 1995. ,
DOI : 10.1083/jcb.130.1.127
Oncogene, 2005. ,
An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis, Blood, vol.103, issue.5, pp.1829-1866, 2004. ,
DOI : 10.1182/blood-2003-05-1510
URL : https://hal.archives-ouvertes.fr/inserm-00130207
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone, Blood, vol.103, issue.8, pp.3148-57, 2004. ,
DOI : 10.1182/blood-2003-06-1984
URL : https://hal.archives-ouvertes.fr/inserm-00129502
Characterization of the Heparin-Binding Properties of IL-6, The Journal of Immunology, vol.165, issue.10, pp.5671-5680, 2000. ,
DOI : 10.4049/jimmunol.165.10.5671
Syndecan-Regulated Receptor Signaling, The Journal of Cell Biology, vol.19, issue.5, pp.995-1003, 2000. ,
DOI : 10.1016/S0955-0674(98)80038-0
Heparan sulfate proteoglycans and heparanase???partners in osteolytic tumor growth and metastasis, Matrix Biology, vol.23, issue.6, pp.341-52, 2004. ,
DOI : 10.1016/j.matbio.2004.08.004
A gene atlas of the mouse and human protein-encoding transcriptomes, Proceedings of the National Academy of Sciences, vol.34, issue.3, pp.6062-6069, 2004. ,
DOI : 10.1038/ng1171
Large scale and clinical grade purification of syndecan-1+ malignant plasma cells, Journal of Immunological Methods, vol.205, issue.1, pp.73-79, 1997. ,
DOI : 10.1016/S0022-1759(97)00056-2
CD44 variant isoforms are involved in plasma cell adhesion to bone marrow stromal cells, Leukemia, vol.16, issue.1, pp.135-178, 2002. ,
DOI : 10.1038/sj.leu.2402336
Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells, Oncogene, vol.21, issue.16, pp.2584-92, 2002. ,
DOI : 10.1038/sj.onc.1205355
A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1, British Journal of Haematology, vol.94, issue.2, pp.318-341, 1996. ,
DOI : 10.1046/j.1365-2141.1996.d01-1811.x
their specific ligands NRG1-2, and their co-receptor syndecan-1 ,